Zomedica Corp. (NYSEAMERICAN:ZOM – Get Free Report) was down 5.5% during mid-day trading on Thursday . The stock traded as low as $0.14 and last traded at $0.15. Approximately 6,710,856 shares traded hands during trading, an increase of 36% from the average daily volume of 4,936,473 shares. The stock had previously closed at $0.16.
Zomedica Price Performance
The firm has a market cap of $137.49 million, a PE ratio of -3.51 and a beta of 0.97.
Insider Buying and Selling at Zomedica
In other news, VP Russell Kevin Klass purchased 299,993 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were acquired at an average cost of $0.16 per share, with a total value of $47,998.88. Following the completion of the acquisition, the vice president now owns 2,000,050 shares of the company’s stock, valued at $320,008. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 4.19% of the company’s stock.
Institutional Investors Weigh In On Zomedica
Zomedica Company Profile
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Featured Stories
- Five stocks we like better than Zomedica
- Buy P&G Now, Before It Sets A New All-Time High
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- MarketBeat Week in Review – 8/12 – 8/16
- Utilities Stocks Explained – How and Why to Invest in Utilities
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.